Journal
MOLECULAR THERAPY
Volume 27, Issue 5, Pages 974-985Publisher
CELL PRESS
DOI: 10.1016/j.ymthe.2019.03.005
Keywords
-
Categories
Funding
- Bill & Melinda Gates Foundation [OPP1163327]
- Emerging Infectious Disease NIH Training Grant [T32-AI055400]
- Bill and Melinda Gates Foundation [OPP1163327] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
Zika virus (ZIKV) infection is endemic to several world regions, and many others are at high risk for seasonal outbreaks. Synthetic DNA-encoded monoclonal antibody (DMAb) is an approach that enables in vivo delivery of highly potent mAbs to control infections. We engineered DMAb-ZK190, encoding the mAb ZK190 neutralizing antibody, which targets the ZIKV E protein DIII domain. In vivo-delivered DMAb-ZK190 achieved expression levels persisting >10 weeks in mice and >3 weeks in non-human primate (NHPs), which is protective against ZIKV infectious challenge. This study is the first demonstration of infectious disease control in NHPs following in vivo delivery of a nucleic acid-encoded antibody, supporting the importance of this new platform.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available